|
|
 |
||
|
||
 |
|
|
|
Press Release - October 28, 2003. |
|||
Press releases |
QuantomiX gears up to product launching in the United States appoints Raffi Werner as COO TEL AVIV, ISRAEL - OCTOBER 28, 2003 - Quantomix (www.quantomix.com), which develops and markets capsules for rapid high resolution imaging of cells and tissues, has appointed Raffi Werner as its COO. Mr. Werner was previously CEO of Lumenis America and General Manager of Laser Industries, where he oversaw manufacturing operations and sales of medical devices. Quantomix recently completed a financing round of $3.5 million, led by Vitalife, the Israeli life sciences venture capital fund, in which Pitango, and SFKT participated. "Our strategy is to build a profitable business in a relatively short time by selling to the research market, while developing the larger drug discovery and diagnostics markets. Raffi's proven experience and capabilities will enable us to meet our expansion targets," said Dr. Ory Zik, Quantomix CEO. Mr. Werner said, that he was joining Quantomix to build the infrastructure needed to transform the company from an inventor of a unique technology to a manufacturing and revenue generating entity. "I have taken a keen interest in QuantomiX because of its huge potential. I believe we have the product range and technology to fully leverage what we feel is a significant need of the life sciences market," he added About QuantomiX Quantomix, founded in 2001 by CEO Dr. Ory Zik and Board Chairman Dr. Michael Brunstein, has developed a revolutionary technology that enables direct high resolution imaging of cells and tissue biopsies in research, patient care and drug discovery. The company's patented QX- capsule technology has solved the 50 year-old problem of direct imaging hydrated samples in an electron microscope. The technology is based on a capsule that contains a powerful nanotechnology-based membrane that completely isolates wet samples from the vacuum in the microscope chamber, while enabling electron microscopy of samples held in water or any other liquid medium at atmospheric pressure. The platform, now at the Beta development stage in leading research institutes in the U.S. and Israel, is set to be marketed first in the U.S and then in Europe and Japan.
For more information please contact: |
||